Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/Bullous Pemphigoid

Dermatologic

Bullous Pemphigoid (BP) Clinical Trials and Treatments

Also called BP, autoimmune blistering, subepidermal blistering

Bullous pemphigoid (BP) is an autoimmune blistering disorder characterized by formation of large, tense blisters on an erythematous or urticarial base due to autoimmune attack on basement membrane proteins. The disease is caused by IgG autoantibodies against hemidesmosomal proteins, particularly BP180 (type XVII collagen, 180-kilodalton ectodomain) and BP230 (bullous pemphigoid antigen 1, 230kDa), which are structural components of hemidesmosomes anchoring basal keratinocytes to the basement membrane.

In plain words, bullous pemphigoid is an autoimmune skin disease where the immune system attacks proteins that anchor the top layer of skin. This causes large blisters and strong itching, often on the lower belly and inner thighs.

Get an email when new Bullous Pemphigoid trials open or the FDA decides. Get alerts

Bullous Pemphigoid

Where treatments stand, from ClinicalTrials.gov and FDA labels

Also 1 study with no phase, like observational studies.

FDA review0

No decision pending. FDA calendar

FDA-approved medicines1

Dupixent

Bullous Pemphigoid has 1 FDA-approved medicine, 3 open or active clinical trials (2 recruiting), and no pending FDA decision.

Labels checked October 21, 2026. Corticosteroids and immune globulins count once each.Download the data

Latest for Bullous Pemphigoid

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

More about Bullous Pemphigoid

These autoantibodies bind to the basement membrane zone, trigger complement activation, and recruit inflammatory cells including neutrophils and eosinophils, leading to subepidermal blister formation with characteristic preservation of the basal cell layer (unlike pemphigus where blisters form intraepidermally). Blisters are typically large and tense with intact roofs that don't rupture easily, commonly affecting flexural areas (armpits, groin), lower abdomen, inner thighs, and lower legs.

Keep reading about Bullous Pemphigoid

Oral mucosa is involved in approximately 25% of cases but typically less severely than in pemphigus vulgaris. Intense pruritus is a characteristic and often debilitating feature. Direct immunofluorescence shows linear IgG and C3 deposition at the basement membrane zone, a key finding for diagnosis. Indirect immunofluorescence and serologic testing confirm circulating autoantibodies.

What are the symptoms of Bullous Pemphigoid?

These are common symptoms of Bullous Pemphigoid, and how strong they are varies from person to person.

  • Large tense blisters on flexural skin
  • Urticarial or eczematous plaques
  • Intense pruritus
  • Erosions and crusting
  • Oral mucosal involvement
  • Involvement of lower abdomen and inner thighs

Who gets Bullous Pemphigoid?

Bullous pemphigoid primarily affects elderly individuals over age 60, though the condition can occur at any age from childhood through advanced age. The incidence increases markedly with age.

The condition affects males and females equally across age groups. It is more common in Caucasians, though cases occur in all ethnic groups. Some cases are associated with underlying malignancy (paraneoplastic BP, particularly in older patients). Autoimmune mechanisms appear to be triggered by medications or environmental factors in some cases.

Next steps: find trials you might fitsee approved treatmentsget help payingget alerts

Which medicines are FDA-approved for Bullous Pemphigoid?

There is currently 1 FDA-approved medication for Bullous Pemphigoid.

Dupixent
dupilumab
Sanofi-Aventis U.S. LLC
Search

Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for Bullous Pemphigoid

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

Finding labs...

Trusted Bullous Pemphigoid resources

Reputable organizations and medical references for learning more about Bullous Pemphigoid, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for Bullous Pemphigoid

Use this Bullous Pemphigoid clinical trial finder to see the 2 studies recruiting patients and 1 not yet recruiting in the United States and worldwide, with eligibility criteria in plain English. Of these, 2 test a treatment and 1 is an observational study or registry; each card says which. Every trial comes from ClinicalTrials.gov.

Jump to the trial list, the site map or the pipeline timeline.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

3 active trials worldwide
Filter:
Sort:
RecruitingTreatment trialPhase 1Updated a few months agoNCT06371417

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

Intervention: RAY121

Sponsor: Chugai Pharmaceutical

This Phase 1b basket trial will investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary efficacy of RAY121, a inhibitor of classical complement pathway, after multiple dose administration in patients with immunological diseases suc...

Ages 18 Years to 85 Years
Started Aug 2024Updated 3 months agoEst. Mar 2027 (~4 months)
RecruitingObservational study, no treatment givenNo updates in a whileNCT02753777

Autoimmune Blistering Diseases Study

Intervention: Questionnaires

Sponsor: University of Pennsylvania

Pemphigus and bullous pemphigoid (BP) are severe autoimmune blistering diseases (AIBD) that pose a critical need for new therapeutic approaches. Clinical trials in pemphigus and BP will require the availability of validated disease severity measures that can be used to define primary outcomes.

Ages 18 Years+3 locations
Started Apr 2016Updated 7 months agoEst. Jan 2030 (~3y 1m)
Not yet recruitingTreatment trialPhase 3Hasn't posted an update in over a yearNCT07210554

Study of Stapokibart Injection in Subjects With Moderate to Severe Bullous Pemphigoid

Intervention: Stapokibart injection, Placebo

Sponsor: Chengdu Kangnuoxing Biopharma,Inc.

This study is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of Stapokibart in subjects with Moderate to Severe Bullous Pemphigoid.

Ages 18 Years to 90 Years1 location
Expected to start Nov 2025Updated 1 year agoEst. Mar 2028 (~1y 4m)
Find Bullous Pemphigoid trials near you, ranked by distance →
Active trial locations11 cities in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.
+3 more

Trial Pipeline

Jan 2021 to Jan 2030
2021
2023
2025
2027
2029
now
Phase 1
Phase 3
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about Bullous Pemphigoid trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run a Bullous Pemphigoid foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

Bullous Pemphigoid patient communities

Facebook groups, Reddit communities and YouTube channels where Bullous Pemphigoid patients, caregivers and advocacy groups talk.

Companies developing Bullous Pemphigoid treatments

Drugmakers that list Bullous Pemphigoid in their rare disease portfolio, 6 in all.

Questions people ask about Bullous Pemphigoid